Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia

Chimeric antigen receptor (CAR) T-cell therapies that specifically target the CD19 antigen have emerged as a highly effective treatment option in patients with refractory B-cell hematological malignancies. Safety and efficacy outcomes from the pivotal prospective clinical trials of axicabtagene cilo...

Descripción completa

Detalles Bibliográficos
Autores principales: Myers, G Doug, Verneris, Michael R, Goy, Andre, Maziarz, Richard T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8047987/
https://www.ncbi.nlm.nih.gov/pubmed/33846220
http://dx.doi.org/10.1136/jitc-2020-002056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8047987/
https://www.ncbi.nlm.nih.gov/pubmed/33846220
http://dx.doi.org/10.1136/jitc-2020-002056

Ejemplares similares